Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Targeting PGLYRP1 in cancer and autoimmunity

Nature Immunology volume 24, pages 1785–1786 (2023)Cite this article

Subjects

Immune checkpoint inhibitors provide beneficial anti-tumor immunity but risk immune-related adverse events occurring in normal tissues. Notably, selective deletion of PGLYRP1, a protein expressed by several immune cells, protects against tumor cell growth and autoimmunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Postow, M. A., Sidlow, R. & Hellmann, M. D. N. Engl. J. Med. 378, 158–168 (2018).

    Article  CAS  PubMed  Google Scholar 

  2. Schnell, A. et al. Nat. Immunol. https://doi.org/10.1038/s41590-023-01645-4 (2023).

    Article  PubMed  Google Scholar 

  3. Dziarski, R. & Gupta, D. Innate Immun 16, 168–174 (2010).

    Article  CAS  PubMed  Google Scholar 

  4. Yashin, D. V. et al. J. Biol. Chem. 290, 21724–21731 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Singer, M. et al. Cell 166, 1500–1511.e9 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chihara, N. et al. Nature 558, 454–459 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Salama, A. D. et al. J. Exp. Med. 198, 71–78 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chitnis, T. et al. J. Clin. Investig. 107, 575–583 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Liu, Q., Wang, B. & Zhao, W. Neurology 98, 501–502 (2022).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

C.E.M. is supported by a National Multiple Sclerosis Society Clinician Scientist Development award FAN-2107-38301. S.S.Z. is supported by National Institutes of Health grants 1 R01 AI131624-01A1 and 1 RO1 AI170863-01A1.

Author information

Authors and Affiliations

  1. Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA

    Carson E. Moseley & Scott S. Zamvil

  2. Program in Immunology, University of California, San Francisco, CA, USA

    Carson E. Moseley & Scott S. Zamvil

Authors
  1. Carson E. Moseley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott S. Zamvil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott S. Zamvil.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moseley, C.E., Zamvil, S.S. Targeting PGLYRP1 in cancer and autoimmunity. Nat Immunol 24, 1785–1786 (2023). https://doi.org/10.1038/s41590-023-01649-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01649-0

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer